Digital-Pathology-Today Podcast Por Magpie Communications arte de portada

Digital-Pathology-Today

Digital-Pathology-Today

De: Magpie Communications
Escúchala gratis

Obtén 3 meses por US$0.99 al mes
Digital Pathology Today, the only podcast for professionals interested in the field of digital pathology and artificial intelligence in a clinical setting. This interview-style podcast features industry leaders, key academics, and top pathologists discussing the past, present and future of digital pathology. Hosted by pathologist, Dr. Joseph Anderson, each weekly episode discusses topics from artificial intelligence to regulation and much more. “We hope to bring news and information to anyone interested in the field of digital pathology,” said Digital Pathology Today host, Dr. Joseph Anderson. “With so many advances and innovations taking place, we know that Digital Pathology Today will be a valuable source of information for our listeners.”Copyright Magpie Communications Ciencia Ciencias Biológicas Enfermedades Físicas Higiene y Vida Saludable Política y Gobierno
Episodios
  • October 2025 Digital Pathology Roundup

    October 2025 Digital Pathology Roundup
    Dec 1 2025
    The October 2025 digital pathology roundup with Imogen Fitt of Signify Research is here. Recent activity in digital pathology and AI spans new partnerships, implementations, and product launches. Partnerships: Alpenglow Biosciences & VirDx: Collaborating to create large-scale 3D light-sheet microscopy datasets as ground truth for VirDx’s MRI-based prostate cancer diagnostics, using NVIDIA accelerated computing to tightly link radiology and pathology. Aiforia & Siemens Healthineers (Finland): After a broader European deal, Aiforia signed a local co-marketing/sales agreement with Siemens Healthineers’ Finnish affiliate to drive AI adoption in Finnish pathology as part of precision diagnostics. Implementations: Institut Curie: Entered a one-year agreement, funded by ARS Île-de-France, to use Aiforia’s CE-IVD clinical AI tools in routine pathology to support faster, more consistent diagnoses. One Dorset Pathology (NHS): Signed a 7-year managed equipment service to deploy FUJIFILM SYNAPSE® Pathology on AWS, integrating partners like Sysmex, Menarini, Ibex, Barco, and Augnito. The goal is 100% digital reporting and meeting the UK 10-day histology target by early 2026. Moffitt Cancer Center: Will implement four Pramana high-throughput scanners to support clinical and research work, including cytology and blood smears, with phased adoption through 2027. Ouest Pathologie & Dedalus: Planning the largest French roll-out of the integrated Diamic-DeepUnity LIS + imaging platform across Bretagne/Normandie via a 7-year plan starting December 2025, enabling AI, tele-expertise, and unified image management. Product launches & integrations: Aignostics Atlas H&E-TME: Now generally available, offering rapid, single-cell-level TME readouts and >5,000 metrics per image from routine H&E, initially targeting biopharma research. Proscia & Primaa: Integrated a skin AI module into Proscia’s platform for mitoses, hotspots, perineural invasion, and margin metrics in dermatopathology. PathPresenter: Its vendor-agnostic clinical viewer achieved CE-IVDR marking for primary diagnosis in Europe, complementing its FDA 510(k) and enabling broader EU clinical deployments.
    Más Menos
    13 m
  • September 2025 Digital Pathology Roundup

    September 2025 Digital Pathology Roundup
    Nov 1 2025
    Digital Pathology Roundup – September 2025 Funding: Cyted Health raised €44m Series B led by EQT Life Sciences with Advent Life Sciences and British Business Bank; existing investors Morningside and BGF joined. Funds will drive US expansion, strengthen UK commercialization, and broaden tests beyond EndoSign, its minimally invasive oesophageal cell collection paired with advanced biomarker assays. StratifAI closed €12.5m led by Picus Capital with Alven and others to clinically validate Polaris, a multimodal AI platform that fuses H&E histology, RNA-seq, and outcomes to generate prognostic and predictive spatial insights. Regulatory Approvals: Aiforia obtained CE-IVD for an AI tool detecting lymph node metastases, developed with University of Bern; the company claims up to 40% time savings in cancer staging. Primaa secured CE-IVDR for Cleo Breast, automating biomarker detection on biopsy and surgical specimens and reporting ~15% faster diagnostics; approval enables wider EU deployment and FDA preparation. Ibex earned CE-IVDR for HER2 IHC scoring within its Breast suite, developed with AstraZeneca and Daiichi Sankyo; the suite recognizes 54 breast tissue morphologies. Partnerships and Product Moves: Lunit partnered with Leica Biosystems to place its SCOPR PD-L1 tool in the Aperio AI Store; teamed with Agilent to co-develop AI-powered CDx solutions; and joined CellCarta to offer its pathology AI within CRO clinical trials workflows. Proscia launched Aperture to turn routine diagnostic data into real-time insights for biomarker validation, CDx development, and submissions; it also enhanced Concentriq AP for cytology and partnered with Datexim to add cytology AI. PathAI integrated Mindpeak’s 11 CE-IVD breast and lung tools (plus RUO assays), Stratipath’s CE-IVD prognostic breast model, and Primaa’s CE-IVDR breast and RUO dermpath tools into AISight Dx, further enlarging its CE-IVD ecosystem.
    Más Menos
    13 m
  • August 2025 Digital Pathology Roundup

    August 2025 Digital Pathology Roundup
    Sep 30 2025
    Here is the August Digital Pathology Roundup with Imogen Fitt of Signify Research. 1. Acquisitions: Tempus AI is buying Paige for $81.25M, mostly in stock. Beyond headlines calling it a “data deal,” Tempus gains Paige’s ~7M de-identified whole-slide images plus seasoned AI/regulatory assets: Paige holds FDA Breakthrough Device Designations and De Novo clearances across prostate, lymph node, and PanCancer Detect. Tempus will also assume Paige’s existing Microsoft Azure cloud commitment. Microscope maker Evident acquired AI-enabled scanner vendor Pramana—the first notable scanner-vendor acquisition in a while—prompting fresh questions about how hardware and AI stacks will consolidate. 2. Partnerships: China’s Thorough Future announced a strategic partnership with Leica Biosystems to bring its multi-organ tumor-detection model (lung, stomach, prostate, intestine, lymph nodes) into Leica’s software; details remain light. KFBIO struck a distribution deal with Malaysia’s CytoVision to bring KFBIO’s scanners, AI, and software to Singapore and Brunei. CytoVision, active since 2023 in digitization and education, already works with two Singaporean hospitals, positioning KFBIO for regional traction. Techcyte extended its integration spree: (1) Modella AI’s PathChat co-pilot (and research-only PathChat DX, which has FDA Breakthrough status) to help pathologists summarize reports, interpret images, and query slides; and (2) DeepBio’s prostate and frozen-section algorithms. Initial DeepBio integrations will be RUO, with CE-IVD offerings in the portfolio and U.S. access planned via CLIA labs. 3. Regulatory: ArteraAI secured FDA De Novo authorization for ArteraAI Prostate just 35 days after announcing Breakthrough Device status. It is now the first FDA-authorized AI tool to provide prognostic insights for patients with non-metastatic prostate cancer, and the decision creates a new product code that may streamline pathways for follow-on entrants.
    Más Menos
    13 m
Todavía no hay opiniones